Report Summary: Mrs. Shreya Salunkhe, 30F

What the Report Found

Ultrasound Findings (Clinical History)

• A single solid nodule, 13 x 12 mm in the left lobe of the thyroid - this is small (about 1.3 cm)
• Multiple punctate echogenic foci (tiny bright spots) = microcalcifications within the nodule
• Classified as TR4 (TI-RADS 4) = moderately suspicious on ultrasound
• Small bilateral lymph nodes noted (not described as significantly enlarged)

The TR4 classification and microcalcifications are important - they raise the sonographic suspicion for malignancy above baseline. This is why the FNAC was performed.

Microscopy (What the Pathologist Saw Under the Microscope)

• Four hypocellular smears - meaning the sample had relatively few cells (this is common in follicular-type lesions)
• Scattered clusters of follicular cells with focal nucleomegaly (some cells had larger nuclei than normal - a mild abnormality)
• Scanty colloid (little of the normal thyroid gel-like substance)
• Hemorrhagic background (some blood in the sample - expected with FNAC)

Impression / Diagnosis

What Happens Next - Management Options

1. Repeat FNAC (most common first step)

• Repeat FNAC resolves the diagnosis in more than 50% of Bethesda III cases - many come back as clearly benign on a second sample
• Typically done after 3-6 months

2. Molecular Testing (if available)

• Tests like ThyroSeq v3 or Afirma Gene Expression Classifier can analyze the nodule's genetic makeup
• These can reclassify many Bethesda III nodules as benign (avoiding unnecessary surgery) or confirm high-risk features
• ThyroSeq v3 has ~94% specificity for Bethesda III/IV nodules - a benign result can avoid surgery in up to 61% of patients

3. Diagnostic Lobectomy (surgical removal of the left thyroid lobe)

• Considered if: repeat FNAC remains indeterminate, molecular testing is unavailable, or nodule features are concerning
• Removes the nodule for definitive histopathological diagnosis
• Given the TR4 ultrasound classification + microcalcifications in a 30-year-old, the treating surgeon may lean toward surgery

4. Observation

• Reasonable only if the patient opts against surgery and molecular testing is reassuring
• Requires serial ultrasound monitoring

Key Points to Discuss with the Doctor

1. This is NOT a cancer diagnosis. It is an indeterminate result that requires follow-up.
2. The microcalcifications + TR4 on ultrasound are the more concerning features here and typically prompt a more proactive approach.
3. At age 30, a thorough evaluation is warranted - younger patients with thyroid nodules have a slightly different risk-benefit balance for surgery.
4. Ask about molecular testing availability in your area before committing to surgery - it can help avoid an operation if it returns a low-risk result.
5. The treating endocrinologist or thyroid surgeon should correlate this with TSH levels, T3/T4, and thyroid antibody tests if not already done.

Important: This explanation is for informational purposes only. The family should consult an endocrinologist or endocrine surgeon for personalized management. Do not delay follow-up given the TR4 classification.

How Age 22 Affects This Report

Higher Baseline Malignancy Risk

• TR4 on ultrasound (moderately suspicious)
• Microcalcifications within the nodule
• Focal nucleomegaly on cytology

Longer Life Ahead = Lower Threshold for Definitive Diagnosis

Fertility and Hormonal Considerations

• If lobectomy is performed, one lobe of the thyroid remains and most 22-year-olds maintain normal thyroid function afterward
• Full thyroidectomy (if ever needed) would require lifelong thyroxine replacement - important for future pregnancies
• These factors should be discussed explicitly with the surgeon

Recommended Action Plan for a 22-Year-Old with This Report

Bottom Line

Please consult an endocrinologist or endocrine/head-and-neck surgeon as soon as possible - ideally within the next 1-2 weeks given the TR4 classification.

Treatment for Bethesda III (FLUS) Thyroid Nodule - 22-Year-Old Female

Step 1: Complete the Pre-Treatment Workup (If Not Already Done)

Step 2: Molecular Testing (Recommended First in a 22-Year-Old)

How It Works

• The FNAC material already collected can be sent for genetic analysis
• No additional needle procedure is needed in most cases

Available Tests

Why This Matters for a 22-Year-Old

• If molecular testing returns "benign/low risk" - she can avoid surgery entirely and be monitored with serial ultrasound
• If molecular testing returns "suspicious" (e.g., BRAF V600E mutation, RET fusion) - it confirms the need for surgery and guides how much thyroid to remove
• A 2026 meta-analysis (PMID 42118459) confirms molecular testing significantly reduces unnecessary surgeries in indeterminate nodules

Note: Molecular testing availability may be limited in India currently. If unavailable locally, the treating surgeon will proceed to Step 3 directly.

Step 3: Surgery - The Definitive Treatment

Option A: Diagnostic Left Hemithyroidectomy (Lobectomy) - PREFERRED

• What is done: The entire left lobe of the thyroid (the side with the nodule) + isthmus is surgically removed
• Duration: ~1-2 hours under general anesthesia
• Hospital stay: 1-2 days
• What happens next: The removed lobe is sent for full histopathology

• Preserves one functioning lobe - most patients maintain normal thyroid function without needing lifelong medication
• Lower risk of complications (parathyroid injury causing low calcium, recurrent laryngeal nerve damage causing hoarseness)
• Important for a 22-year-old planning future pregnancies

Option B: Total Thyroidectomy - Only If Specifically Indicated

• Molecular testing shows a high-risk mutation (BRAF + TERT combination)
• The nodule is very large (>4 cm)
• There is confirmed lymph node involvement
• The patient has a strong family history of thyroid cancer
• The contralateral lobe also has suspicious nodules

Step 4: Post-Surgery Management

If Lobectomy is Performed and Benign on Histology:

• Repeat ultrasound in 6-12 months
• Check TSH every 6-12 months (some patients develop hypothyroidism from a single remaining lobe)
• If TSH rises above normal, start levothyroxine (T4) supplementation
• No radioiodine or further treatment needed

If Malignant on Final Histology (e.g., Papillary Thyroid Cancer):

• Completion thyroidectomy (removal of remaining right lobe) - typically done within 6 weeks
• Post-op radioactive iodine (RAI / I-131) ablation - only if the cancer is >1 cm or has high-risk features
• Lifelong levothyroxine therapy (to replace thyroid hormone and suppress TSH slightly)
• Regular follow-up with TSH, thyroglobulin levels, and neck ultrasound

Is Non-Surgical Treatment (Thermal Ablation / RFA) an Option?

• RFA is approved for confirmed benign nodules only (Bethesda II)
• For Bethesda III with TR4 + microcalcifications, malignancy cannot be excluded - ablating a potentially cancerous nodule without histology is dangerous
• A 2025 systematic review (PMID 40658618) confirmed RFA may be considered in Bethesda III only for patients who refuse surgery or are medically unfit - and only with strict long-term follow-up

Summary: What Should Happen in Order

TODAY → Blood tests (TSH, FT4, Anti-TPO)
       ↓
WEEK 1-2 → Consult endocrinologist + thyroid surgeon
           ↓
IF AVAILABLE → Molecular testing of FNAC sample
           ↓
           Benign result? → Watch with serial ultrasound
           Suspicious result? → Proceed to surgery
           ↓
IF UNAVAILABLE → Proceed directly to surgery
           ↓
SURGERY → Left hemithyroidectomy (lobectomy)
           ↓
           Benign histology → Monitoring only
           Malignant → Completion thyroidectomy ± RAI

The final decision must be made by an endocrinologist + endocrine/head-and-neck surgeon together, after reviewing the full clinical picture. Given the age of 22 and the TR4 classification with microcalcifications, most experienced centers would not delay beyond 4-6 weeks.

Causes of Thyroid Nodules and Follicular Lesions

A. Causes of Benign Thyroid Nodules (Most Common)

1. Iodine Deficiency

• The most common cause of thyroid nodules worldwide
• When iodine intake is low, the thyroid cannot make enough hormone
• The pituitary gland releases more TSH (Thyroid Stimulating Hormone) to compensate
• Chronic TSH stimulation drives thyroid cell growth, leading to nodule formation
• Particularly relevant in parts of India where dietary iodine may be suboptimal

2. Excess TSH Stimulation

• Even TSH levels within the upper-normal range are associated with nodule growth and increased malignancy risk
• Any condition that chronically raises TSH (hypothyroidism, Hashimoto's thyroiditis) can drive nodule formation

3. Hashimoto's Thyroiditis (Autoimmune)

• The most common thyroid disease in young women
• The immune system attacks thyroid tissue, causing chronic inflammation
• This can produce pseudo-nodules and can also cause indeterminate cytology on FNAC (mimicking FLUS)
• Relevant here because Anti-TPO antibody testing was recommended for this patient

4. Autonomous (Hyperfunctioning) Nodules

• Mutations in the TSH receptor gene or Gα protein cause a nodule to produce thyroid hormone independently, without needing TSH
• These are almost always benign - the very mutations that drive their growth also push cells toward differentiation (not malignancy)
• Detected by TSH suppression + thyroid scintigraphy ("hot nodule")

5. Simple Colloid / Adenomatous Nodules

• Focal overgrowth of normal follicular thyroid tissue
• No specific cause identified - often incidental findings on ultrasound

B. Causes of Malignant Thyroid Nodules

1. Radiation Exposure - Most Established Environmental Cause

• External radiation to the head, neck, or chest (especially in childhood) causes chromosomal breaks, genetic rearrangements, and loss of tumor-suppressor genes
• Historically used to treat acne, enlarged tonsils/thymus - now known to be dangerous
• Nuclear fallout (radioactive iodine isotopes) - e.g., post-Chernobyl, increases thyroid cancer rates in exposed populations
• Children and adolescents are far more susceptible than adults - directly relevant at age 22 (exposure during childhood has a long latency period of 10-20 years before cancer develops)
• Radiation-associated cancers tend to be multicentric and appear at a younger age

2. Genetic Mutations - The Molecular Engine of Thyroid Cancer

For FLUS/Bethesda III nodules specifically, the most relevant mutations are RAS, PAX8-PPARγ, and RET/PTC rearrangements - these are what molecular tests (ThyroSeq v3, Afirma) look for.

3. Hereditary / Genetic Syndromes

4. Age Under 20 or Over 65

• Both extremes of age independently increase malignancy risk in a thyroid nodule
• At age 22, the patient falls in the young high-risk group
• This is listed explicitly in Harrison's risk factor table for thyroid malignancy

5. Female Sex + Hormonal Factors

• Thyroid nodules are 4-6x more common in women than men
• Estrogen receptors are found on thyroid tissue - hormonal fluctuations (puberty, pregnancy, oral contraceptives) may stimulate thyroid cell growth
• However, being female paradoxically is associated with better prognosis if cancer does develop

6. TSH - The Growth Driver

• Even high-normal TSH (within laboratory reference range) is associated with a statistically higher risk of thyroid cancer in patients with nodules
• This is why TSH level is one of the first tests ordered - a suppressed TSH (low) makes malignancy much less likely

C. Why This Specific Patient May Have Developed This Nodule

1. Iodine status - suboptimal iodine intake during adolescence driving nodule formation
2. Hashimoto's thyroiditis - causing inflammatory pseudo-nodule + indeterminate FNAC result
3. Spontaneous de novo mutation in a follicular cell (most thyroid cancers in young people have no identifiable external cause)
4. Possible childhood radiation exposure - if she received any head/neck radiation or lived near a nuclear facility (worth asking during history)
5. Family history - if a first-degree relative had thyroid or other endocrine cancers

Summary Table

The cause cannot be identified from the FNAC report alone. A thorough clinical history (family history, radiation exposure, diet, other symptoms) taken by the treating doctor is essential to identify contributing factors in this individual case.